| 马 莉,顾中盛,蒋桂平,王 涵,史华慧.奥拉帕利维持治疗对铂敏感复发性卵巢癌患者血清肿瘤标志物和凋亡因子的影响[J].现代生物医学进展英文版,2024,(10):1856-1859. |
| 奥拉帕利维持治疗对铂敏感复发性卵巢癌患者血清肿瘤标志物和凋亡因子的影响 |
| Effect of Olaparib Maintenance Therapy on Serum Tumor Markers and Apoptosis Factors in Patients with Platinum Sensitive Recurrent Ovarian Cancer |
| Received:September 08, 2023 Revised:September 28, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.10.011 |
| 中文关键词: 奥拉帕利 铂敏感复发性卵巢癌 肿瘤标志物 凋亡因子 |
| 英文关键词: Olapali Platinum sensitive recurrent ovarian cancer Tumor markers Apoptosis factor |
| 基金项目:江苏省妇幼健康科研项目（F201921）；南京药学会-常州四药医院药学科研基金项目（2019YX010） |
|
| Hits: 238 |
| Download times: 171 |
| 中文摘要: |
| 摘要 目的：观察奥拉帕利维持治疗对铂敏感复发性卵巢癌患者血清凋亡因子、肿瘤标志物的影响。方法：按照随机数字表法，将2020年1月到2022年1月期间我院收治的80例铂敏感复发性卵巢癌患者分为对照组（n=40）和观察组（n=40）。两组患者均经二线含铂化疗后，经评估达到临床缓解或部分缓解后，对照组患者不予特殊药物处理，观察组则在化疗结束8周内开始口服奥拉帕利作为维持治疗，直至疾病进展或发生不可接受的毒性反应。对比两组的血清肿瘤标志物和凋亡因子水平情况，观察两组不良反应发生率和预后情况。结果：两组治疗后癌胚抗原（CEA）、糖类抗原（CA）125、人附睾蛋白4（HE4）均下降（P<0.05），且观察组低于对照组（P<0.05）。两组治疗后B淋巴细胞瘤-2（Bcl-2）、可溶性细胞凋亡因子（sFas）和Bcl-2结合抗凋亡基因-1（Bag-1）均下降，Bcl-2相关X蛋白（Bax）升高（P<0.05），观察组治疗后Bcl-2、sFas、Bag-1低于对照组，Bax高于对照组（P<0.05）。两组治疗期间各项不良反应发生率对比未见统计学差异（P>0.05）。两组治疗后认知能力、情感健康、社会功能、躯体功能、行为功能评分升高，且观察组的改善幅度大于对照组（P<0.05）。结论：奥拉帕利维持治疗铂敏感复发性卵巢癌患者，可有效改善血清肿瘤标志物和凋亡因子水平，提高患者生存质量，预后良好。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of olaparib maintenance therapy on serum apoptosis factors and tumor markers in patients with platinum sensitive recurrent ovarian cancer. Methods: According to the random number table method, 80 patients with platinum sensitive recurrent ovarian cancer who were admitted to our hospital from January 2020 to January 2022 were divided into control group (n=40) and observation group (n=40). Patients in both groups were treated with second-line platinum-containing chemotherapy, after clinical remission or partial remission was evaluated, patients in control group were not treated with special drugs, while patients in observation group began to take Olaparib orally as maintenance treatment within 8 weeks after chemotherapy until disease progression or unacceptable toxicity. The levels of serum tumor markers and apoptotic factors were compared between two groups, and the incidence of adverse reactions and prognosis were observed. Results: Carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125 and human epididymis protein 4 (HE4) in two groups decreased after treatment (P<0.05), and the observation group was lower than that in control group after treatment (P<0.05). B-cell lymphoma-2 (Bcl-2), soluble apoptosis factor (sFas) and Bcl-2 binding anti-apoptotic gene-1 (Bag-1) decreased, and Bcl-2 related X protein (Bax) increased in both groups after treatment (P<0.05), Bcl-2, sFas and Bag-1 in observation group were lower than those in control group, and Bax was higher than that in control group after treatment (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups during treatment (P>0.05). After treatment, Cognitive ability, Emotional health, Social function, Physical function, and Behavioral function scores increased in both groups, and the improvement in the observation group was greater than that in the control group (P<0.05). Conclusion: Olaparib maintenance therapy in patients with platinum sensitive recurrent ovarian cancer can effectively improve the levels of serum tumor markers and apoptotic factors, improve the quality of life of patients and have a good prognosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
